Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Baltimore Marriott Waterfront

05 feb 2024 7:00 a.m. - 07 feb 2024 1:00 p.m.

700 Aliceanna Street , Baltimore, MD 21202

Global Pharmacovigilance and Risk Management Strategies Conference

Register for 2 or more short courses and save $150 off your registration fee!

Session 5: Safety Management Considerations for Advanced Therapeutics

Session Chair(s)

Mariette  Boerstoel-Streefland, MD, MBA, MS

Mariette Boerstoel-Streefland, MD, MBA, MS

Senior Vice President, Worldwide Safety Officer

Bristol-Myers Squibb Company, United States

Session 5: Safety Management Considerations for Advanced Therapeutics

Learning Objective : In this session you will hear experiences, insights, and perspectives from those working in this field.
  • Identify specific challenges for adequate safety monitoring for advanced therapeutics
  • Gain insights on how to improve your acumen on advanced therapies for your everyday work

Speaker(s)

Kasia  Lobello, MD

Gene Therapy for Duchenne Muscular Dystrophy: Lessons learned (so far) from the fordadistrogene movaparvovec clinical trial program

Kasia Lobello, MD

Pfizer Inc., United States

Safety Risk Lead

Emil Andrei  Cochino, MD, MHS

Safety Management Considerations for Advanced Therapeutics

Emil Andrei Cochino, MD, MHS

European Medicines Agency, Netherlands

Scientific Senior Specialist (Risk Management)

Robert  Sokolic, MD, FACP

Speakers

Robert Sokolic, MD, FACP

Food and Drug Administration, United States

Medical Officer

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.